Advertisement

Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma

  • Byungyoon Yun
    Affiliations
    Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Sang Hoon Ahn
    Affiliations
    Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun–gu, Seoul 03722, Republic of Korea

    Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea

    Yonsei Liver Centre, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea
    Search for articles by this author
  • Juyeon Oh
    Affiliations
    Department of Public Health, Graduate School, Yonsei University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
    Jin-Ha Yoon
    Correspondence
    Corresponding author at: Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
    Footnotes
    1 These authors contributed equally to this work.
    Affiliations
    Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

    Department of Occupational Health, Department of Preventive Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun–gu, Seoul 03722, Republic of Korea
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
    Beom Kyung Kim
    Correspondence
    Corresponding author at: Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun–gu, Seoul 03722, Republic of Korea.
    Footnotes
    1 These authors contributed equally to this work.
    Affiliations
    Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun–gu, Seoul 03722, Republic of Korea

    Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea

    Yonsei Liver Centre, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
      Potent antiviral therapy (AVT) against hepatitis B virus (HBV) can induce regression of liver fibrosis, thereby reducing the development of liver cirrhosis and hepatocellular carcinoma (HCC) [
      • Yim H.J.
      • Kim J.H.
      • Park J.Y.
      • Yoon E.L.
      • Park H.
      • Kwon J.H.
      • et al.
      Comparison of clinical practice guidelines for the management of chronic hepatitis B: when to start, when to change, and when to stop.
      ]. A high recurrence rate even after curative surgical resection of HCC remains a major challenge [
      • Lee J.H.
      • Kim B.K.
      • Park S.Y.
      • Tak W.Y.
      • Park J.Y.
      • Kim D.Y.
      • et al.
      The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma.
      ].

      Keywords

      Abbreviations:

      AVT (antiviral therapy), HBV (hepatitis B virus), HCC (hepatocellular carcinoma), ETV (entecavir), TDF (tenofovir disoproxil fumarate), NHIS (national health insurance service), PS (propensity score), IPTW (inverse probability treatment weighting), HR (hazard ratio), CI (confidence interval), CHB (chronic hepatitis B), HCV (hepatitis C virus), HIV (human immunodeficiency virus), LC (liver cirrhosis), ALD (alcoholic liver disease), TAF (tenofovir alafenamide), IFN (interferon)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Yim H.J.
        • Kim J.H.
        • Park J.Y.
        • Yoon E.L.
        • Park H.
        • Kwon J.H.
        • et al.
        Comparison of clinical practice guidelines for the management of chronic hepatitis B: when to start, when to change, and when to stop.
        Clin Mol Hepatol. 2020; 26: 411-429
        • Lee J.H.
        • Kim B.K.
        • Park S.Y.
        • Tak W.Y.
        • Park J.Y.
        • Kim D.Y.
        • et al.
        The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma.
        Eur J Intern Med. 2021; 89: 48-55
        • Lee S.W.
        • Choi J.
        • Kim S.U.
        • Lim Y.S.
        Entecavir versus tenofovir in patients with chronic hepatitis B: enemies or partners in the prevention of hepatocellular carcinoma.
        Clin Mol Hepatol. 2021; 27: 402-412
        • van Erpecum K.J.
        • Sonneveld M.J.
        Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: is tenofovir or entecavir preferred?.
        Eur J Intern Med. 2021; 89: 27-29
        • Choi J.
        • Jo C.
        • Lim Y.S.
        Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
        Hepatology. 2021; 73: 661-673
        • Wang X.H.
        • Hu Z.L.
        • Fu Y.Z.
        • Hou J.Y.
        • Li W.X.
        • Zhang Y.J.
        • et al.
        Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
        J Gastroenterol. 2022; 57: 185-198
        • Tsai M.C.
        • Wang C.C.
        • Lee W.C.
        • Lin C.C.
        • Chang K.C.
        • Chen C.H.
        • et al.
        Tenofovir is superior to entecavir on tertiary prevention for BCLC stage 0/A hepatocellular carcinoma after curative resection.
        Liver Cancer. 2022; 11: 22-37
        • de Groen R.A.
        • McPhee F.
        • Friborg J.
        • Janssen H.L.
        • Boonstra A.
        Endogenous IFNlambda in viral hepatitis patients.
        J Interf Cytokine Res. 2014; 34: 552-556
        • Bruno S.
        • Thompson A.J.
        • Critelli R.
        • Crosignani A.
        • Rossi S.
        • De Lisi S.
        • et al.
        Interferon lambda-3 is not associated with clinical outcome in patients with HCV-induced compensated cirrhosis: a long-term cohort study.
        Antivir Res. 2015; 113: 27-32
        • Korean Association for the Study of the Liver (KASL)
        KASL clinical practice guidelines for management of chronic hepatitis B.
        Clin Mol Hepatol. 2019; 25: 93-159